**[CTEP Staff Publications]{.underline}**

**2008**

Brave, M., Goodman, V., Kaminskas, E., Farrell, A., **Timmer, W.,**
Pope, S., Harapanhalli, R., Saber, H., Morse, D., Bullock, J., Men, A.,
Noory, C., Ramchandani, R., Kenna, L., Booth, B., Gobburu, J., Jiang,
X., Sridhara, R., Justice, R., and Pazdur, R. (2008). Sprycel for
chronic myeloid leukemia and Philadelphia chromosome-positive acute
lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
*Clinical Cancer Research,* 14(2), 352-359.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18223208>

Come, S., Buzdar, A., Ingle, J., Johnston, S., Brodie, A., Coombes, R.,

> Mille, W., Pritchard, K., Winer, E., **Zujewski,** **J.,** and Goss,
> P. (2008). Endocrine and targeted manipulation of breast cancer:
> summary statement from the Sixth Cambridge Conference. *Cancer,* 112(3
> Suppl), 673-8.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18072254>

Eng-Wong, J., and **Zujewski, J**. (2008). Current NCI-sponsored
cooperative trials of

> endocrine therapy in breast cancer. *Cancer,* 112(3 Suppl), 723-9.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18072276>

Eng-Wong, J., Orzano-Birgani, J.A., Chow, C.K., Venzon, D., Yao, J.,
Galbo, C.E.,

> **Zujewski,** **J.,** and Prindiville, S. (2008). The effect of
> raloxifene on mammographic density and breast MRI in premenopausal
> women at increased risk for breast cancer. *Cancer Epidemiology,
> Biomarkers and Prevention,* 7, 1696-701.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18583470>

Goss, P.E., Ingle J.N., Pater J.L., Martino S., Robert N.J., Muss, H.B.,
Piccart, M.J., Castiglione, M., Sherpherd, L.E., Pritchard, K.I.,
Livingston, R.B., Davidson, N.E., Norton, L., Perez, E.A., **Abrams,
J.S.,** Cameron, D.A., Palmer, M.J., and Tu, D. (2008). Late extended
adjuvant treatment with letrozole improves outcome in early-stage breast
cancer in women who complete 5 years of tamoxifen. *Journal of Clinical
Oncology,* 26, 1948-1955.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18332475>

Gralow, J.R., **Zujewski, J.,** and Winer, E. (2008). Preoperative
therapy in invasive

> breast cancer: reviewing the state of the science and exploring new
> research directions. *Journal of Clinical Oncology,* 26(5), 696-7.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18258975>

Houghton, P., Morton, C., Kolb, E., Gorlick, R., Lock, R., Carol, H.,
Reynolds, C., Maris,

> J., Keir, S., Billups, C., and **Smith, M.** (2008). Initial testing
> (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical
> testing program. *Pediatric Blood and Cancer,* 50(4), 799-805.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17635004>

Houghton, P., Morton, C., Kolb, E., Lock, R, Carol,. H., Reynolds, C.,
Keshelava, N.,

> Maris, J., Keir, S., Wu, J., and **Smith, M.** (2008). Initial testing
> (stage 1) of the proteasome inhibitor bortezomib by the pediatric
> preclinical testing program. *Pediatric Blood and Cancer,* 50(1),
> 37-45.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17420992>

Hunsberger, S., Freidlin, B., and **Smith, M.** (2008). Complexities in
interpretation of osteosarcoma clinical trial results. *Journal of
Clinical Oncology,* 26(18), 3103-3104.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18565905>

Ingle, J.N., Tu, D., Pater, J.L., Muss, H.B., Martino, S., Robert, N.J.,
Piccart, M.G., Castiglione, M., Shepherd, L.E., Pritchard, K.I.,
Livingston, R.B., Davidson, N.E., Norton, L., Perez, E.A., **Abrams,
J.S.,** Cameron, D.A., Palmar, M.J., and Goss, P.E. (2008). Intent to
treat analysis of the placebo-controlled trial of Letrozole for extended
adjuvant therapy in early breast cancer: NCIC CTG MA.17. *Annals of
Oncology,* 19, 872-882.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18332043>

Keir, S., Morton, C., Billups, C., **Smith, M.,** Houghton, P., and
Gururangan, S. (2008). Initial testing of VNP40101M (Cloretazine) by the
Pediatric Preclinical Testing Program. *Pediatric Blood and Cancer*,
51(3), 439-44.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18493996>

Kolb, E., Gorlick, R., Houghton, P., Morton, C., Lock, R., Carol, H.,
Reynolds, C., Maris, J., Keir, S., Billups, C., and **Smith, M.**
(2008). Initial testing (stage 1) of a monoclonal

> antibody (SCH 717454) against the IGF-1 receptor by the pediatric
> preclinical testing program. *Pediatric Blood and Cancer,* 50(6),
> 1190-1197.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18260118>

Kolb, E., Gorlick, R., Houghton, P., Morton, C., Lock, R., Tajbakhsh,
M., Reynolds, C., Maris, J., Keir, S., Billups, C., and **Smith, M.**
(2008). Initial testing of dasatinib by the pediatric preclinical
testing program. *Pediatric Blood and Cancer,* 50(6), 1198-1206.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17914733>

**Little, R., Denicoff, A.**, and **Trimble, E.** (2008). Reversible
features of cervical cancer in human immunodeficiency virus infection:
impaired access, impaired surveillance, impaired immunity, impaired
outcomes (editorial). *Cancer,* 112(12), 2627-30.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18429005>

Lock, R., Carol, H., Houghton, P., Morton, C., Kolb, E., Gorlick, R.,
Reynolds, C., Maris,

> J., Keir, S., Wu, J., and **Smith, M.** (2008). Initial testing
> (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical
> testing program. *Pediatric Blood and Cancer,* 50(6), 1181-1189.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18085673>

Maris, J., Courtright, J., Houghton, P., Morton C., Gorlick, R., Kolb,
E., Lock, R.,

> Tajbakhsh, M., Reynolds, C., Keir, S., Wu, J., and **Smith, M.**
> (2008). Initial testing of the VEGFR inhibitor AZD2171 by the
> pediatric preclinical testing program. *Pediatric Blood and Cancer,*
> 50, 581-587.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17457854>

Maris, J., Courtright, J., Houghton, P., Morton, C., Kolb, E., Lock, R.,
Tajbakhsh, M.,

> Reynolds, C., Keir. S., Wu, J., and **Smith, M.** (2008). Initial
> testing (stage 1) of sunitinib by the Pediatric Preclinical Testing
> Program. *Pediatric Blood and Cancer,* 51(1), 42-48. Website:
> <http://www.ncbi.nlm.nih.gov/pubmed/18293383>

**Murgo, A.J.,** Kummar, S., Rubinstein, L., Gutierrez, M., Collins, J.,
Kinders, R., Parchment, R.E., Ji, J., Steinberg, S.M., Yang, S.X.,
Hollingshead, M., **Chen, A.,** Helman, L., Wiltrout, R., Tomaszewski,
J.E. and Doroshow, J.H. (2008).** **Designing Phase 0 Cancer Clinical
Trials. *Clinical Cancer Research,* 14, 3675-3682.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18559582>

Neale, G., Su, X., Morton, C., Phelps, D., Gorlick, R., Lock, R.,
Reynolds, C., Maris, J., Friedman, H., Dome, J., Khoury, J., Triche, T.,
Seeger, R., Gilbertson. R., Khan, J., **Smith, M.,** and Houghton, P.
(2008). Molecular characterization of the Pediatric Preclinical Testing
Panel. *Clinical Cancer Research,* 14(14), 4572-4583.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18628472>

**Smith, M.,** Morton, C., Phelps, D., Girtman, K., Neale, G., and
Houghton, P. (2008). SK-

> NEP-1 and Rh1 are Ewing family tumor lines. *Pediatric Blood and
> Cancer,* 50(3), 703-706. Website:
> <http://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed&cmd=retrieve&dopt=AbstractPlus&list_uids=17154184>

**Smith, M.**, Morton, C., Phelps, D., et al. (2008). Stage 1 testing
and pharmacodynamic

> evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by
> the Pediatric Preclinical Testing Program. *Pediatric Blood and
> Cancer,* 51(1), 34-41.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18260120>

Stroup, A., Harlan, L., and **Trimble, E.** (2008). Demographic,
clinical and treatment

> trends among women diagnosed with vulvar cancer in the United States.
> *Gynecologic Oncology,* 108(3), 577-83.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18155274>

Tajbakhsh, M., Houghton, P., Morton, C., Kolb, E., Gorlick, R., Maris,
J., Keir, S., Wu, J.,

> Reynolds, C., **Smith, M.,** and Lock, R. (2008). Initial testing of
> cisplatin by the pediatric preclinical testing program. *Pediatric
> Blood and Cancer,* 50(5), 992-1000.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17554786>

**Trimble, E.,** Harlan, L., Gius, D., Stevens, J., and Schwartz, S.
(2008). Patterns of care for women with cervical cancer in the United
States. *Cancer,* 113(4), 743-9.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18618500>

Wolff, A.C., Berry, D., Carey, L.A., Colleoni, M., Dowsett, M., Ellis,
M., Garber, J.E.,

> Mankoff, D., Paik, S., Pusztai, L., Smith, M.L., and **Zujewski,**
> **J.** (2008). Research issues affecting pre-operative systemic
> therapy for operable breast cancer. *Journal of Clinical Oncology*,
> 26(5), 806-13.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18258990>

**2007**

Whiteford, C., Bilke, S., Greer, B., et al. (2007). Credentialing
Preclinical Pediatric

> Xenograft Models Using Gene Expression and Tissue Microarray Analysis.
> *Cancer Research,* 67(1), 32-40.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17210681>

Aragon-Ching, J. and **Zujewski,** **J.** (2007). CNS Metastasis: An old
problem in a new guise. *Clinical* *Cancer Research,* 13(6), 1644-1647.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17363516>

Hudis, C., Barlow W., Costantino, J., Gray R., Pritchard K., Chapman J.,
Sparano J., Hunsberger, S., Enos R., Gelber R., and **Zujewski, J.**
(2007). Proposal for standardized definitions for efficacy end points in
adjuvant breast cancer trials: the STEEP system. *Journal of Clinical
Oncology,* 25(15), 2127-32.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17513820>

Freidlin, F., Korn, E. L., Hunsberger, S., Gray, R., Saxman, S., and
**Zujewski, J.** (2007). Progression-Free Survival in Unblinded
Randomized Trials. *Journal of Clinical Oncology,* 25, 2122-2126.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17513819>

**Trimble, E.,** Davis, J., DiSaia, P., et al. (2007). Clinical trials
in gynecological cancer.

> *International Journal of Gynecological Cancer,* 17(3), 547-56.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17504371>

Gaffney, D., Du Bois, A., Narayan, K., Reed, N., Toita, T., Pignata, S.,
Blake, P., Portelance, L., Sadoyze, A., Pötter, R., Colombo, A.,
Randall, M., Mirza, M., and **Trimble, E.** (2007). Practice patterns of
radiotherapy in cervical cancer among member groups of the Gynecologic
Cancer Intergroup (GCIG). International Journal of Radiation Oncology
Biology, Physics, 68(2), 485-90.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17336465>

Rapkiewicz, A., Espina V., **Zujewski, J.,** Lebowitz, P.F., Filie, A.,
Wulfkuhle, J., Camphausen, K., Petricoin E.F., Liotta, L., and Abati, A.
(2007). The needle in the haystack: Application of breast Fine Needle
Aspirate samples to quantitative protein microarray technology. *Cancer
(Cancer Cytopathology),* 111, 173-84.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17487852>

Kummar, S., Gutierrez, M., Gardner, E., Donovan, E., Hwang, K., Chung,
E., Lee, M., Maynard, K., Kalnitskiy, M., **Chen, A.,** Melillo, G.,
Ryan, Q., Conley, B., Figg, W., Trepel, J., **Zwiebel, J.,** Doroshow
J., and **Murgo, A.** (2007). Phase I Trial of MS-275, a Histone
Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors
and Lymphoid Malignancies. *Clinical Cancer Res*earch, 13, 5411-5417.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17875771>

Rubinstein, L., **Dancey, J.,** Korn, E., et al. (2007). Early average
change in tumor

> size in a phase 2 trial: efficient endpoint or false promise? *Journal
> of the National Cancer Institute,* 99(19), 1422-1423.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17895470>

Minasian, L., O'Mara, A., Reeve, B., **Denicoff, A.,** Kelaghan, J.,
Rowland, J., and

> **Trimble, E.** (2007). Health-related quality of life and symptom
> management research sponsored by the National Cancer Institute.
> *Journal of Clinical Oncology,* 25(32) 5128-32. Website:
> <http://www.ncbi.nlm.nih.gov/pubmed/17991932>

Lipscomb, J., Reeve, B., Clauser, S., **Abrams, J.,** Watkins-Bruner,
D., Burke, L.B., Denicoff, A., Ganz, P., Gondek, K., Minasian, L.,
O\'Mara, A., Revicki, D.A., Rock, E., Rowland, J., Sgambati, M., and
**Trimbl**e**, E.** (2007). Patient-Reported Outcomes Assessment in
Cancer Trials: Taking Stock, Moving Forward. *Journal of Clinical
Oncology,* 25, 5133-40.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17991933>

Clauser, S., Ganz, P., Lipscomb, J., and Reeve, B. (2007).
Patient-reported outcomes assessment in cancer trials: taking stock,
moving forward. *Journal of Clinical Oncology*, 25(32), 5133-40.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17991919>

Farley, J., Harlan, L., Clegg, L., Larsen, W., and **Trimble, E.**
(2007). Patterns of care for cervical cancer patients treated in the
U.S. military health care system. *Journal of Reproductive Medicine,*
52(11), 1040-5.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/18161403>

Premkumar, A., Venzon, D.J., Avila, N., Johnson, D.V., Remaley, A.T.,
Forman, M.R., Eng-Wong, J., **Zujewski, J.,** and Stratton, P. (2007).
Gynecologic and hormonal effects of raloxifene in pre-menopausal
subjects at high risk for developing breast cancer. *Fertility and
Sterility*, 88(6),1637-44.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17662283>

Houghton, P., Morton, C., Tucker, C., et al. (2007). The Pediatric
Preclinical Testing

> Program: description of models and early testing results. *Pediatric
> Blood and Cancer,* 49(7), 928-940.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17066459>

## **Kinders, R., Parchment, R., Ji, J., Kummar, S.,** Murgo, A., **Gutierrez, M., Collins, J., Rubinstein, L., Pickeral, O., Steinberg, S., Yang, S., Hollingshead, M.,** Chen, A., **Helman, L., Wiltrout, R., Simpson, M., Tomaszewski, J., and Doroshow, J. (2007).** Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice. ***Molecular Interventions,*** 7, 325-334. 

## Website: [**http://www.ncbi.nlm.nih.gov/pubmed/18199854**](http://www.ncbi.nlm.nih.gov/pubmed/18199854)

**2006**

Mariotto, A., Feuer, E., Harlan, L., and **Abrams, J.** (2006).
Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for
Breast Cancer in the U.S. using Estrogen Receptor Information:
1975-1999. *Journal of the National Cancer Institute Monographs,* 36,
7-15. Website: <http://www.ncbi.nlm.nih.gov/pubmed/17032888>

**Trimble, E.** and **Christian, M.** (2006). Intraperitoneal
chemotherapy for women with

> advanced epithelial ovarian carcinoma. *Gynecologic Oncology,*100(1),
> 3-4.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/16368439>

Wedam, S., Low, J. A., Yang, S. X., Chow, C. K., Chyke, P., Danforth,
D., Hewitt, S. M., Berman, A., Steinberg, S., Liewehr, D.L., Plehn, J.,
Doshi, A., Thomasson, D., McCarthy, N., Koeppen, H., Sherman, M.,
**Zujewski, J.,** Camphausen, K., Chen, H., and Swain, S.M. (2006).
Anti-angiogenic and anti-tumor effects of bevacizumab in inflammatory
and locally advanced breast cancer patients. *Journal of Clinical
Oncology,* 24(5), 769-777. Website:
<http://www.ncbi.nlm.nih.gov/pubmed/16391297>

Harlan, L., Clegg, L., **Abrams, J.,** Stevens, J., and Ballard-Barbash,
R. (2006). Community Based Use of Chemotherapy and Hormonal Therapy for
Early Stage Breast Cancer: 1987-2000. *Journal of Clinical Oncology,*
24(6), 872-7.

Website: <http://www.ncbi.nlm.nih.gov/pubmed/16484696>

**Trimble E.** and **Christian M.** (2006). Cancer treatment and the
older patient. *Clinical*

> *Cancer Research,* 12 (7 Pt 1), 1956-7.
>
> Website:
> <http://www.ncbi.nlm.nih.gov/pubmed/16609002?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum>

Disis, M., Rivkin, S., Baron, A., Markman, M., Connolly, D., Ueland, F.,
Kohn, E.,

> Trimble, E., and Berek, J. (2006). Progress in ovarian cancer
> research: proceedings of the 5^th^ Biennial Ovarian Cancer Research
> Symposium. *International Journal of Gynecological Cancer,* 16(2),
> 463-9.

Website: <http://www.ncbi.nlm.nih.gov/pubmed/16681712>

**Smith, Malcolm**. (2006). Double trouble: cancer in twins. *Pediatric
Blood and Cancer,* 46(4), 412-413.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/16155936>

Faupel-Badger, J., Prindiville, S., Venzon, D., Vonderhaar, B.,
**Zujewski, J.,** and Eng-Wong, J. (2006). Effects of raloxifene on
circulating prolactin and estradiol levels in premenopausal women at
high risk for developing breast cancer. *Cancer Epidemiology, Biomarkers
& Prevention,* 15(6), 1-6.

> Website:
> <http://www.ncbi.nlm.nih.gov/pubmed/16775175?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum>

**Zujewski, J.,** Enos, M.A., and Mason, S. (2006). Clinical trials
referral resource. Current phase III breast cancer clinical trials.
*Oncology (Williston Park, N.Y.).* 20(7), 696, 700, 702. Website:
<http://www.ncbi.nlm.nih.gov/pubmed/16841794>

**Chen,** **H.X.,** **Mooney,** **M.,** **Boron,** **M.,** Vena, D.,
Mosby, K., **Grochow,** **L.,** Jaffe, C., Rubinstein, L., **Zwiebel,**
**J.,** and **Kaplan,** **R.S.** (2006). Phase II multicenter trial of
bevacizumab plus fluorouracil and leucovorin in patients with advanced
refractory colorectal cancer: an NCI Treatment Referral Center Trial
TRC-0301. *Journal of Clinical Oncology,* 21, 3354-60. Website:
<http://www.ncbi.nlm.nih.gov/pubmed/16849749>

Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D, Liu
ET, Chow C, and **Zujewski, J.** (2006). Effect of raloxifene on bone
mineral density in premenopausal women at increased risk of breast
cancer. *Journal of Clinical Endocrinology and Metabolism.* 91(10),
3941-3946.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/16868059>

Fountain, J., **Trimble, E.,** and Birrer, M. (2006). The 2005 Ovarian
Cancer State of the Science Meeting Summary and discussion of session
recommendations. *Gynecologic Oncology,*103 (2 Suppl 1): S23-5.

> Website:
> <http://www.ncbi.nlm.nih.gov/pubmed/17027068?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum>

**Trimble, E.** and Alvarez, R. (2006). Intraperitoneal chemotherapy and
the NCI clinical

> announcement. *Gynecologic Oncology,* 103 (2 Suppl 1):S18-9.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17027073>

Chatterton, R. **Zujewski, J.,** Mateo, E.T., Eng-Wong, J., and Jordan,
V.C. (2006). Effect of Raloxifene on Salivary Sex Steroid Concentrations
in premenopausal Women. *Journal of Endocrinology.* 191(3), 599-604.

> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17170217>

Alberts, D., Markman. M., Muggia, F., Ozols, R., Eldermire, E., Bookman,
M., Chen, T.,

> Curtin, J., Hess, L., Liebes, L., Young, R., and **Trimble, E.**
> (2006). Proceedings of a GOG workshop on intraperitoneal therapy for
> ovarian cancer. *Gynecologic Oncology,* 103(3), 783-92.
>
> Website: <http://www.ncbi.nlm.nih.gov/pubmed/17070570>

Hazarika, M., Jiang, X., Liu, Q., Lee, S.L., Ramchandani,R., Garnett,
C., Orr, M.S., Sridhara, R., Booth, B., Leighton, J.K., **Timmer, W.,**
Harapanhalli, R., Dagher, R., Justice, R., and Pazdur, R. (2008).Tasigna
for Chronic and Accelerated Phase Philadelphia Chromosome Positive
Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib.
*Clinical Cancer Research,* 14(9), 5325-5331.

> Web site:
> <http://www.ncbi.nlm.nih.gov/pubmed/18765523?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum>

##